Accuracy - Wren Laboratories

The NETest: A meta-analysis of the accuracy of an mRNA blood-based neuroendocrine tumor biomarker

Analysis of ten studies indicates the NETest is an accurate (>95%) biomarker suitable for clinical use in NET disease management, exhibiting utility as an IVD to establish a diagnosis and monitor therapeutic efficacy.

Neuroendocrine Neoplasia Diagnosis: mRNA biomarker NETest exhibits 3-5 times greater accuracy than Chromogranin A

NETest, a multigenomic mRNA biomarker exhibiting ~99% accuracy in NEN disease identification; is far more accurate than CgA (19–33%) and should be considered the biomarker standard of care.

NETest demonstrates surgical and clinical utility

NETest proves superior to CgA as effective marker for imaging, solid tumor grading, post surgery disease status and residual tumor detection.

The NETest: A meta-analysis of the accuracy of an mRNA blood-based neuroendocrine tumor biomarker

Neuroendocrine Neoplasia Diagnosis: mRNA biomarker NETest exhibits 3-5 times greater accuracy than Chromogranin A

NETest demonstrates surgical and clinical utility

Success!